Integra LifeSciences Holdings Corporation IART recently announced preliminary revenues for third-quarter 2020. The company is scheduled to release detailed financial results for the period on Oct 28.
Integra projects third-quarter 2020 revenues in the band of $368-$370 million. This indicates an organic revenue decline of 1.8% to 2.7% on a reported basis. The Zacks Consensus Estimate for the same is currently pegged at $343 million.
This preliminary figure marks a significant recovery from the second quarter reported decline of 32.6% and organic decline of 31.3% year over year. According to the company, the sales improvement in the third quarter was broad-based across the major franchises.
Following this announcement, shares of the company improved 0.7% to $48.81 at yesterday’s close.
Integra LifeSciences, during the second-quarter earnings call, was upbeat about its improvement in monthly sales trends but wary about the uncertainties related to the pandemic’s impacts on the full year. Hence, the company did not provide any financial guidance for the year. For the third quarter, the company earlier noted that it does not expect the recovery rates for all its markets and product lines to be the same.
As of now, the Zacks Consensus Estimate for the third-quarter 2020 adjusted earnings per share is pegged at 58 cents and that for the full year is $2.80. Full-year revenues are projected at $1.53 billion.
During the first two months of the first quarter, sales were in line with expectations. However, since March, as the outbreak took a graver turn, demand for the company’s surgical procedures declined significantly. This was because healthcare providers started to reallocate resources to address the surging demand caused by the COVID-19 outbreak. According to Integra, there was a dramatic sales decline that occurred as soon as surgical procedures were postponed on a wide scale.
In the third quarter, Integra, despite projecting year-over-year declines, assured about the magnitude of this decline not at the same rate as in the second quarter as many procedures in which its products are employed cannot be deferred for more than 90 days.
Shares of the company have improved 4.3% in the past three months compared with the industry’s 7.8% rise.
Zacks Rank & Key Picks
Currently, Integra carries a Zacks Rank #3 (Hold).
A few better-ranked stocks from the broader medical space include QIAGEN N.V. QGEN, Thermo Fisher Scientific Inc. TMO and Globus Medical, Inc. GMED.
QIAGEN’s long-term earnings growth rate is estimated at 22.3%. It currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Thermo Fisher’s long-term earnings growth rate is estimated at 15.5%. It currently carries a Zacks Rank #2 (Buy).
Globus Medical’s long-term earnings growth rate is estimated at 13%. The company presently carries a Zacks Rank #2.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Integra LifeSciences Holdings Corporation (IART) : Free Stock Analysis Report
QIAGEN N.V. (QGEN) : Free Stock Analysis Report
Thermo Fisher Scientific Inc. (TMO) : Free Stock Analysis Report
Globus Medical, Inc. (GMED) : Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research